Organization
Vall d'Hebron University Hospital (HUVH)
2 abstracts
Abstract
First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma.Org: Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Medical Oncology Department, Hospital Universitario 12 De Octubre, Hospital Clinic of Barcelona, Hospital Clinic i Provincial de Barcelona,
Abstract
Influence of age, sex and tumor type in the likelihood of inclusion in early clinical trials.Org: Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology, Vall d´Hebron University Hospital, Universitat Autònoma de Barcelona,